Recent Updates
Recently added Catalysts
IMCR Positive Sentiment Score: 75/100

Immunocore to present at the Bank of America Securities 2023 Health Care Conference

Key Takeaway: Immunocore Holdings Plc has announced its participation in the Bank of America Securities 2023 Health Care Conference. The presentation is scheduled for May 10, 2023, and will be accessible via webcast on the company's website. Immunocore focuses on T cell receptor bispecific immunotherapies, with several clinical programs and one approved therapy for uveal melanoma.

Market Sentiment Analysis

POSITIVE FACTORS

  • Immunocore is pioneering a novel class of TCR bispecific immunotherapies.
  • The company is developing a deep pipeline across multiple therapeutic areas.
  • KIMMTRAK is already approved in multiple regions for treating uveal melanoma.

Full Press Release Details

Immunocore to present at the Bank of America Securities 2023 Health Care Conference
(OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 03 May 2023) Immunocore Holdings Plc (Nasdaq: IMCR), a commercial-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infectious diseases and autoimmune conditions, today announced that management will present at the Bank of America Securities 2023 Health Care Conference.
The fireside chat is scheduled for Wednesday, May 10, 2023, at 5:00 p.m. Pacific Daylight Time (PDT).
The fireside chat will be webcast live and can be accessed in the ‘Investors’ section of Immunocore’s website at www.immunocore.com. Following the event, a replay of the presentation will be made available for a limited time.
Immunocore is a commercial-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies called ImmTAX – Immune mobilizing monoclonal TCRs Against X disease – designed to treat a broad range of diseases, including cancer, autoimmune, and infectious disease. Leveraging its proprietary, flexible, off-the-shelf ImmTAX platform, Immunocore is developing a deep pipeline in multiple therapeutic areas, including four clinical stage programs in oncology and infectious disease, advanced pre-clinical programs in autoimmune disease and multiple earlier pre-clinical programs. The Company’s most advanced oncology TCR therapeutic, KIMMTRAK has been approved for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma in the United States, European Union, Canada, Australia, and the United Kingdom.
Sébastien Desprez, Head of Communications
T: +44 (0) 7458030732
Follow on Twitter: @Immunocore
Consilium Strategic Communications (corporate and financial)
Mary-Jane Elliott/ Chris Welsh/Jessica Hodgson
T: +44 (0)203 709 5700
Clayton Robertson, Head of Investor Relations

Tags

Frequently Asked Questions

When will Immunocore present at the Health Care Conference?

Immunocore will present on May 10, 2023, at 5:00 p.m. PDT.

How can I watch the Immunocore presentation?

The presentation will be webcast live on Immunocore’s website.

What is Immunocore’s main focus?

Immunocore specializes in TCR bispecific immunotherapies for various diseases.

What is the purpose of ImmTAX therapy?

ImmTAX is designed to mobilize the immune system against diseases.

Which therapy has Immunocore advanced in oncology?

KIMMTRAK is Immunocore’s leading therapy approved for certain melanoma patients.

Last updated: May 3, 2023